Estados financieros detallados de Adlai Nortye Ltd. (ANL): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 100.0%, margen operativo -113.3%, margen neto -114.5%.
Al precio actual de $15.52, ANL presenta beneficios negativos (P/E no significativo) y un ROE del -21.82%. La capitalización bursátil es de $824M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | $45.7M | 0 | 0 | 0 | $5.0M |
| Coste de Ventas | $1.5M | $1.5M | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$1.5M | -$1.5M | $45.7M | 0 | 0 | 0 | $5.0M |
| I+D | $13.3M | $19.0M | $42.1M | $54.5M | $58.2M | $44.9M | $32.8M |
| Generales y Administrativos | $4.3M | $5.6M | $12.4M | $12.4M | $14.8M | $9.4M | $7.8M |
| Gastos Operativos | $17.6M | $24.6M | $54.4M | $67.3M | $72.6M | $52.9M | $40.7M |
| Beneficio Operativo | -$19.1M | -$26.1M | -$8.6M | -$67.3M | -$72.6M | -$52.9M | -$35.7M |
| EBITDA | -$15.9M | -$60.1M | -$53.5M | -$56.3M | -$106.2M | -$48.1M | -$32.6M |
| Gastos por Intereses | $466145 | $1.7M | $1.3M | $433000 | $791000 | $1.9M | $1.5M |
| Beneficio Antes de Impuestos | -$17.8M | -$63.4M | -$56.7M | -$58.8M | -$109.2M | -$51.9M | -$35.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$17.8M | -$63.4M | -$56.7M | -$58.8M | -$109.2M | -$51.9M | -$35.5M |
| BPA | $-2.10 | $-7.62 | $-4.62 | $-4.77 | $-15.42 | $-4.89 | $-3.33 |
| BPA Diluido | $-2.10 | $-7.62 | $-4.62 | $-4.77 | $-15.42 | $-4.89 | $-3.33 |
| Acciones en Circulación (Diluidas) | $8.5M | $8.5M | $12.3M | $12.3M | $6.8M | $10.6M | $10.7M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $6.0M | $24.2M | $64.1M | $42.8M | $91.5M | $60.9M | $23.8M |
| Inversiones a Corto | 0 | $241000 | $53.8M | $21.3M | $7.0M | $7000 | 0 |
| Cuentas por Cobrar | $91591 | $394048 | $1.9M | $346000 | $359000 | $1.2M | $1.4M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $6.4M | $28.6M | $124.5M | $66.3M | $101.2M | $64.1M | $26.9M |
| Inmovilizado Material | $3.3M | $6.6M | $6.6M | $5.9M | $3.8M | $2.7M | $3.0M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $115422 | $11000 | $97000 | $89000 | $63000 | $40000 | $19000 |
| Activos Totales | $10.8M | $36.7M | $131.7M | $72.6M | $130.2M | $71.3M | $34.4M |
| Cuentas por Pagar | $5.3M | $1.5M | $3.0M | $13.1M | $14.3M | $10.1M | $12.6M |
| Deuda a Corto | $10.9M | $9.1M | $10.5M | $4.3M | $30.4M | $26.3M | $25.2M |
| Pasivos Corrientes | $20.3M | $88.0M | $17.5M | $312.7M | $49.7M | $45.4M | $41.6M |
| Deuda a Largo | $634250 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $80.2M | $168.3M | $317.1M | $313.9M | $55.1M | $45.8M | $42.8M |
| Reservas | -$86.6M | -$159.2M | -$209.4M | -$268.2M | -$377.4M | -$429.3M | -$464.8M |
| Patrimonio Neto | -$69.4M | -$131.6M | -$185.4M | -$241.3M | $75.0M | $25.5M | -$8.3M |
| Deuda Total | $11.9M | $11.0M | $13.3M | $6.5M | $31.5M | $27.2M | $26.4M |
| Deuda Neta | $5.9M | -$13.5M | -$104.6M | -$57.5M | -$67.0M | -$33.7M | $2.6M |
| Capital Circulante | -$13.9M | -$59.4M | $107.0M | -$246.3M | $51.5M | $18.7M | -$14.7M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$17.8M | -$63.4M | -$56.7M | -$58.8M | -$104.9M | -$51.9M | -$35.6M |
| Amortizaciones | $1.5M | $1.5M | $1.8M | $2.0M | $2.2M | $1.9M | $1.4M |
| Compensación en Acciones | 0 | $2.3M | $3.4M | $6.1M | $4.3M | $2.5M | 0 |
| Cambio en Capital Circulante | $3.0M | -$11.3M | $250000 | $15.2M | $6.1M | -$5.5M | -$2.3M |
| Flujo de Caja Operativo | -$14.9M | -$34.6M | -$3.0M | -$43.2M | -$56.7M | -$51.8M | -$33.5M |
| Inversiones (CapEx) | -$184953 | -$1.6M | -$1.1M | -$1.3M | -$200000 | -$170000 | -$187491 |
| Adquisiciones | $434 | $10141 | -$102000 | -$2000 | 0 | -$4.2M | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$15.1M | -$36.2M | -$4.2M | -$44.5M | -$56.9M | -$52.0M | -$33.7M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -100.0% | ||||||
| Crecimiento Beneficio Neto (anual) | -255.5% | +10.6% | -3.7% | -85.8% | +52.5% | +31.5% | |
| Crecimiento BPA (anual) | -262.9% | +39.4% | -3.2% | -223.3% | +68.3% | +31.9% | |
| Cambio en Acciones (anual) | +0.0% | +45.0% | +0.0% | -44.7% | +56.4% | +0.2% | |
| Crecimiento FCF (anual) | -139.7% | +88.5% | -971.0% | -27.8% | +8.6% | +35.1% | |
| Margen Bruto | 100.0% | 100.0% | |||||
| Margen Operativo | -18.9% | -714.0% | |||||
| Margen EBITDA | -117.0% | -652.5% | |||||
| Margen Neto | -124.0% | -710.6% | |||||
| Margen FCF | -9.1% | -674.5% | |||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-1.78 | $-4.27 | $-0.34 | $-3.62 | $-8.36 | $-4.89 | $-3.16 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $8.5M | $8.5M | $12.3M | $12.3M | $6.8M | $10.6M | $10.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -21.82% |
| Rentabilidad sobre capital invertido | -9.23% |
| Rentabilidad sobre activos | -9.07% |
| Margen bruto | 100.00% |
| Margen operativo | -113.28% |
| Margen neto | -114.48% |
Salud financiera
| Deuda / Patrimonio | 0.12 |
| Ratio corriente | 9.55 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -7.14 | -1.97 | -3.25 | -3.14 | -0.58 | -0.55 | -0.43 |
| P/VC | -1.83 | -0.97 | -1.00 | -0.76 | 0.82 | 1.12 | -1.82 |
| P/V | 0.00 | 0.00 | 4.03 | 0.00 | 0.00 | 0.00 | 3.03 |
| Margen Bruto | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Margen Operativo | 0.0% | 0.0% | -18.9% | 0.0% | 0.0% | 0.0% | -714.0% |
| Margen Neto | 0.0% | 0.0% | -124.0% | 0.0% | 0.0% | 0.0% | -710.6% |
Empresas relacionadas: ADAP · ADTX · AIMD · APLM · BLRX · GOVX · ICU
Explorar sector: Healthcare · Biotechnology
Más secciones de ANL: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones